Get the Stockscreener App
3.49
4.64%
-0.17
Geron Corp stock is traded at $3.49, with a volume of 24.93M.
It is down -4.64% in the last 24 hours and down -12.53% over the past month.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
See More
Previous Close:
$3.66
Open:
$3.61
24h Volume:
24.93M
Relative Volume:
2.98
Market Cap:
$2.11B
Revenue:
$29.48M
Net Income/Loss:
$-201.19M
P/E Ratio:
-10.26
EPS:
-0.34
Net Cash Flow:
$-216.50M
1W Performance:
-9.59%
1M Performance:
-12.53%
6M Performance:
-21.75%
1Y Performance:
+61.57%
1-Day Range:
$3.455
$3.685
1-Week Range:
$3.455
$4.00
52-Week Range:
$1.64
$5.34
Geron Corp Stock (GERN) Company Profile
Name
Geron Corp
Sector
Industry
Phone
(650) 473-7700
Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Compare GERN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GERN
Geron Corp
|
3.49 | 2.11B | 29.48M | -201.19M | -216.50M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Geron Corp Stock (GERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Initiated | Leerink Partners | Outperform |
| Apr-30-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-29-24 | Initiated | TD Cowen | Buy |
| Mar-15-24 | Reiterated | Needham | Buy |
| Sep-12-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-28-23 | Initiated | Goldman | Neutral |
| Oct-28-22 | Initiated | Wedbush | Outperform |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Nov-02-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Resumed | B. Riley Securities | Buy |
| Aug-03-20 | Initiated | Stifel | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Sep-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-15-19 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-09-19 | Upgrade | Needham | Hold → Buy |
| Jan-31-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-02-18 | Downgrade | B. Riley FBR | Buy → Neutral |
| Jul-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-13-16 | Reiterated | FBR & Co. | Outperform |
| Sep-13-16 | Reiterated | FBR Capital | Outperform |
| Dec-07-15 | Reiterated | Piper Jaffray | Overweight |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Jun-12-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-12-14 | Downgrade | MLV & Co | Buy → Hold |
| Dec-10-13 | Reiterated | MLV & Co | Buy |
| Dec-10-13 | Upgrade | Needham | Hold → Buy |
| Nov-08-13 | Reiterated | MLV & Co | Buy |
| Oct-16-13 | Initiated | MLV & Co | Buy |
| Aug-30-12 | Initiated | Stifel Nicolaus | Buy |
| Jun-28-12 | Initiated | Needham | Hold |
View All
Geron Corp Stock (GERN) Latest News
Geron (NASDAQ:GERN) Stock Price Down 2.5%Here's Why - MarketBeat
Barclays PLC Has $5.90 Million Stock Holdings in Geron Co. (NASDAQ:GERN) - MarketBeat
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Geron Corporation (NASDAQ:GERN) is a favorite amongst institutional investors who own 72% - Yahoo Finance
Geron (NASDAQ:GERN) Shares Up 3.7%Here's Why - MarketBeat
Geron Co. (NASDAQ:GERN) Short Interest Down 5.4% in November - MarketBeat
Geron's SWOT analysis: biotech stock shows promise amid challenges - Investing.com
Geron Co. (NASDAQ:GERN) Shares Sold by MML Investors Services LLC - MarketBeat
State Street Corp Grows Stock Position in Geron Co. (NASDAQ:GERN) - MarketBeat
Exome Asset Management LLC Invests $4.11 Million in Geron Co. (NASDAQ:GERN) - MarketBeat
Geron announces positive CHMP opinion for Rytelo - Yahoo Finance
Geron's (GERN) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
World Investment Advisors LLC Increases Stake in Geron Co. (NASDAQ:GERN) - MarketBeat
Geron's RYTELO nears EU approval for certain blood cancers - Investing.com
Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS - Yahoo Finance
Geron Co. (NASDAQ:GERN) Shares Bought by Wellington Management Group LLP - MarketBeat
Stifel sustains Buy on Geron, steady stock target amid ASH updates - Investing.com Canada
What is Leerink Partnrs' Forecast for Geron FY2026 Earnings? - MarketBeat
Geron Co. (NASDAQ:GERN) Shares Bought by BNP Paribas Financial Markets - MarketBeat
Is Geron Corporation (GERN) the Best NASDAQ Penny Stock to Buy Right Now? - Insider Monkey
Imetelstat shows promise for LR-MDS patients post other therapies - Investing.com
Geron's RYTELO Shows Strong Safety Profile in Phase 1 Myelofibrosis Trial at ASH Meeting - StockTitan
HC Wainwright Reaffirms "Buy" Rating for Geron (NASDAQ:GERN) - MarketBeat
Analyst Scoreboard: 4 Ratings For Geron - Benzinga
The Manufacturers Life Insurance Company Sells 220,414 Shares of Geron Co. (NASDAQ:GERN) - MarketBeat
Geron Co. (NASDAQ:GERN) Stock Position Lessened by Fmr LLC - MarketBeat
Geron Co. (NASDAQ:GERN) Shares Sold by RA Capital Management L.P. - MarketBeat
RTW Investments LP Makes New $200.27 Million Investment in Geron Co. (NASDAQ:GERN) - MarketBeat
Janus Henderson Group PLC Acquires 13,163,889 Shares of Geron Co. (NASDAQ:GERN) - MarketBeat
Geron's SWOT analysis: biopharmaceutical stock poised for growth amid challenges - Investing.com
Geron Co. (NASDAQ:GERN) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Walleye Capital LLC Purchases New Shares in Geron Co. (NASDAQ:GERN) - MarketBeat
Geron (NASDAQ:GERN) Trading Down 3.1%Here's What Happened - MarketBeat
Vestal Point Capital LP Purchases New Stake in Geron Co. (NASDAQ:GERN) - MarketBeat
Geron Co. (NASDAQ:GERN) Shares Sold by Ally Bridge Group NY LLC - MarketBeat
Acuta Capital Partners LLC Acquires New Shares in Geron Co. (NASDAQ:GERN) - MarketBeat
Intech Investment Management LLC Invests $1.10 Million in Geron Co. (NASDAQ:GERN) - MarketBeat
Geron Co. (NASDAQ:GERN) Shares Purchased by Algert Global LLC - MarketBeat
Geron to Present at Evercore ISI HealthCONx Conference This December - StockTitan
Geron Corp. (GERN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts - Insider Monkey
12 NASDAQ Stocks with Biggest Upside Potential According to Analysts - Insider Monkey
Geron Grants 1M Stock Options to New Hires at $3.99 Exercise Price | GERN Stock News - StockTitan
Geron: A Strong Launch And Financial Deals Make It Attractive (NASDAQ:GERN) - Seeking Alpha
Akin Advises Pharmakon Advisors in its $250 Million Debt Financing for Geron Corporation - Akin Gump Strauss Hauer & Feld LLP
First Turn Management LLC Takes $14.19 Million Position in Geron Co. (NASDAQ:GERN) - MarketBeat
RA Capital Management's Strategic Acquisition of Geron Corp Shar - GuruFocus.com
Deep Track Capital's Strategic Reduction in Geron Corp Holdings - GuruFocus.com
RTW INVESTMENTS, LP Acquires New Stake in Geron Corp - GuruFocus.com
GERNGeron Corp Latest Stock News & Market Updates - StockTitan
Geron's SWOT analysis: oncology biotech stock poised for growth - Investing.com
Geron Strengthens Leadership: Top Oncology Expert Dr. Eid Joins as EVP of R&D | GERN Stock News - StockTitan
Geron Corp Stock (GERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Geron Corp Stock (GERN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GRETHLEIN ANDREW J | EVP, Chief Operating Officer |
Jul 08 '24 |
Sale |
4.56 |
674,348 |
3,073,004 |
0 |
| Feller Faye | EVP, Chief Medical Officer |
Jun 10 '24 |
Option Exercise |
1.19 |
287,900 |
341,693 |
155,400 |
| Feller Faye | EVP, Chief Medical Officer |
Jun 10 '24 |
Sale |
4.63 |
287,900 |
1,334,129 |
0 |
| Kapur Anil | EVP, Corp Strategy & CCO |
Jun 10 '24 |
Option Exercise |
1.06 |
421,875 |
447,188 |
421,875 |
| Kapur Anil | EVP, Corp Strategy & CCO |
Jun 10 '24 |
Sale |
4.64 |
421,875 |
1,959,609 |
0 |
| SCARLETT JOHN A | Chairman, President and CEO |
Jun 04 '24 |
Option Exercise |
2.54 |
600,000 |
1,524,000 |
600,000 |
| SCARLETT JOHN A | Chairman, President and CEO |
Jun 04 '24 |
Sale |
4.00 |
600,000 |
2,400,000 |
600,000 |
| LAWLIS V BRYAN | Director |
May 15 '24 |
Option Exercise |
1.94 |
35,000 |
67,900 |
35,000 |
| LAWLIS V BRYAN | Director |
May 15 '24 |
Sale |
3.75 |
35,000 |
131,250 |
0 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):